Structurally modified 'dietary flavonoids': Are these viable drug candidates for chemoprevention?

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 67-70

  Srinivas, Nuggehally R ^a  

^a ClinTec India International Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APIGENIN; CHRYSIN; FLAVONE DERIVATIVE; FLAVONOID; GENISTEIN; NATURAL PRODUCT; PHYTOESTROGEN; POLYPHENOL DERIVATIVE; QUERCETIN; SELENIUM; TAMOXIFEN; VITAMIN D; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CHEMICAL MODIFICATION; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TRANSPORT; ESOPHAGUS CANCER; FOOD COMPOSITION; FRUIT; HUMAN; MONOTHERAPY; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; SULFONATION; VEGETABLE; BIOAVAILABILITY; CHEMISTRY; DIET; NEOPLASM; NUTRITIONAL VALUE;

ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; DIET; FLAVONOIDS; HUMANS; NEOPLASMS; NUTRITIVE VALUE;

EID: 65549160008     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236065     Document Type: Review

References (30)

1. Burgess M, de Alwis DP. The true face of the revolution in oncology drug development: A personal reflection. Curr Clin Pharmacol 2007; 2: 31-5.
2. Siess MH, Le Bon AM, Canivenc-Lavier MC, Suschetet M. Mechanisms involved in the chemoprevention of flavonoids. Biofactors 2000; 12: 193-9.
3. Steele VE, Pereira MA, Sigman CC, Kelloff GJ. Cancer chemoprevention agent development strategies for genistein. J Nutr 1995; 125: 713S-6S.
4. Linseise J, Rohrmann S. Biomarkers of dietary intake of flavonoids and phenolic acids for studying diet-cancer relationships in humans. Eur J Nutr 2008; 47: 60-8.
5. Suganuma M, Okabe S, Sueoka N, et al. Green tea and cacer chemoprevention. Mutat Res 1999; 428: 339-44.
6. Cooke D, Steward WP, Gescher AJ, Marczylo T. Anthocyans from fruits and vegetables - does bright colour signal cancer chemopreventive activity? Eur J Cancer 2005; 41: 1931-40.
7. http://www.phytochemicals.info/phytochemicals/flavonoids.php (this website provides a description of various types of phytochemicals including flavonoids).
8. Riemersma RA, Rice-Evans CA, Tyrrell RM, Clifford MN, Lean MEJ. Tea flavonoids and cardiovascular health. Q J Med 2001; 94: 277-82.
9. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicology 2006; 20: 187-210.
10. Prasain JK, Barnes S. Metabolism and bioavailability of flavonoids in chemprevention: current analytical strategies and future prospectus. Mol Pharm 2007; 4: 846-64.
11. Ta N, Walle T. Aromatase inhibition by bioavailable methylated flavones. J Steroid Biochem Mol Biol 2007; 107: 127-9.
12. Walle T, Wen X, Walle UK. Improving metabolic stability of cancer chemopreventive polyphenols. Toxicology 2007; 3: 379-88.
13. Wen X, Walle T. Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica 2006; 36: 387-97.
14. Wen X, Walle T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 2006; 34: 1786-92.
15. Walle T. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass. Semin Cancer Biol 2007; 17: 354-62.
16. Walle T, Ta N, Kawamori T, Wen X, Tsuji PA, Walle UK. Cancer chemopreventive properties of orally bioavailable flavonoids - methylated versus unmethylated flavones. Biochem Pharmacol 2007; 73: 1288-96.
17. Walle T. Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption. Mol Pharm 2007; 4: 826-7.
18. Cai H, Boocock DJ, Steward WP, Geschler AJ. Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemother Pharmacol 2007; 60: 257-66.
19. Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 2006; 313: 144-9.
20. Smith CM, Graham RA, Krol WL, et al. Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 cells. J Pharmacol Exp Ther 2005; 315: 1256-64.
21. Walle T, Otake Y, Brubaker JA, Walle UK, Halushka PV. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol 2001; 51: 143-6.
22. García-Quetglas E, Azanza JR, Sadaba B, Munoz MJ, Gil I, Campanero MA. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 2007; 55: 122-30.
23. Landis-Piwowar KR, Milacic V, Dou QP. Relationship between the methylation status of dietary flavonoids and their growth-inhibitory and apoptosis-inducing activities in human cancer cells. J Cell Biochem 2008; 105: 514-23.
24. Wen X, Walle T. Cytochrome P450 1B1, a novel chemopreventive target for benzo1pyrene-initiated human esophageal cancer. Cancer Lett 2007; 246: 109-14.
25. Walle T, Walle UK. Novel methoxylated flavone inhibitors of cytochrome P450 1B1 in SCC-9 human oral cancer cells. J Pharm Pharmacol 2007; 59: 857-62.
26. Zheng Q, Hirose Y, Yoshimi Y, et al. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. J Cancer Res Clin Oncol 2002; 128: 539-46.
27. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostrate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007; 16: 2193-2203.
28. McClain MR, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J. Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol 2006; 44: 56-80.
29. Kim H, Yoon YJ, Shon JH, et al. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab Dispos 2006; 34: 521-3.
30. Srinivas NR. Clinical use of St. John's wort: drug-drug interaction potential of the marketed products and challenges for drug development. Asian J Pharmacodyn Pharmacokin 2008; 8: 109-26.